Kiniksa Pharmaceuticals, Ltd. KNSA
We take great care to ensure that the data presented and summarized in this overview for Kiniksa Pharmaceuticals, Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KNSA
View all-
Black Rock Inc. New York, NY4.19MShares$79.9 Million0.0% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.2MShares$61.1 Million10.07% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.14MShares$59.7 Million1.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.98MShares$56.8 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.81MShares$53.5 Million0.7% of portfolio
-
Rubric Capital Management LP New York, NY2.2MShares$41.8 Million1.48% of portfolio
-
State Street Corp Boston, MA1.89MShares$36 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.52MShares$28.9 Million0.03% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V81.46MShares$27.8 Million0.03% of portfolio
-
Braidwell LP Stamford, CT1.39MShares$26.5 Million0.89% of portfolio
Latest Institutional Activity in KNSA
Top Purchases
Top Sells
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Insider Transactions at KNSA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
747
+8.06%
|
-
|
|
Apr 26
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-2.58%
|
$8,653
$17.88 P/Share
|
|
Apr 26
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
991
+4.78%
|
-
|
|
Apr 08
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-4.04%
|
$13,447
$17.9 P/Share
|
|
Apr 08
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,694
+12.1%
|
-
|
|
Apr 08
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-1.51%
|
$12,461
$17.9 P/Share
|
|
Apr 08
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,497
+4.89%
|
-
|
|
Apr 08
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,075
-6.07%
|
$69,275
$17.9 P/Share
|
|
Apr 08
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+12.96%
|
-
|
|
Apr 08
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.63%
|
$13,617
$17.9 P/Share
|
|
Apr 08
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,726
+2.1%
|
-
|
|
Apr 08
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-7.25%
|
$28,322
$17.9 P/Share
|
|
Apr 08
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,932
+14.6%
|
-
|
|
Apr 08
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-7.67%
|
$23,001
$17.9 P/Share
|
|
Apr 08
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+12.32%
|
-
|
|
Apr 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
514
-2.96%
|
$9,766
$19.7 P/Share
|
|
Apr 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,750
+9.15%
|
-
|
|
Apr 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
880
-5.49%
|
$16,720
$19.7 P/Share
|
|
Apr 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,612
+9.14%
|
-
|
|
Apr 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,084
-5.38%
|
$20,596
$19.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 18.9K shares |
|---|---|
| Exercise of conversion of derivative security | 253K shares |
| Payment of exercise price or tax liability | 29.2K shares |
|---|---|
| Open market or private sale | 224K shares |